The observed sensitivity is also comparable to those of multiple myeloma and MYCN-amplified neuroblastoma cell lines, reported to be potentially JQ1-sensitive tumor types (Delmore et al., 2011; Puissant et al., 2013), and substantially higher than those of lung adenocarcinoma and MYCN-WT neuroblastoma cell lines (Lockwood et al., 2012; Puissant et al., 2013). The gene discussed is MYCN; the disease is plasma cell myeloma.